Drug Profile

CLR 1800

Alternative Names: CLR1800

Latest Information Update: 28 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellectar Biosciences; Pierre Fabre
Developer Cellectar Biosciences
Class Antineoplastics; Drug conjugates; Phospholipid ethers; Small molecules
Mechanism of Action Protein biosynthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
09 Mar 2021 Cellectar Biosciences has patent protection for Phospholipid-ether analogues in Japan
12 Jun 2020 Cellectar Biosciences has patent pending for composition of matter and use of phospholipid-ether analogs in Europe _

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com